SG11201608430RA - Novel macrocyclic compounds - Google Patents

Novel macrocyclic compounds

Info

Publication number
SG11201608430RA
SG11201608430RA SG11201608430RA SG11201608430RA SG11201608430RA SG 11201608430R A SG11201608430R A SG 11201608430RA SG 11201608430R A SG11201608430R A SG 11201608430RA SG 11201608430R A SG11201608430R A SG 11201608430RA SG 11201608430R A SG11201608430R A SG 11201608430RA
Authority
SG
Singapore
Prior art keywords
macrocyclic compounds
novel macrocyclic
novel
compounds
macrocyclic
Prior art date
Application number
SG11201608430RA
Inventor
Ulrich Lücking
Pierre Wasnaire
Arne Scholz
Philip Lienau
Gerhard Siemeister
Christian Stegmann
Ulf Bömer
Kunzeng Zheng
Ping Gao
Gang Chen
Jiajun Xi
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52824234&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201608430R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SG11201608430RA publication Critical patent/SG11201608430RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16Halogenated acetic acids
    • C07C53/18Halogenated acetic acids containing fluorine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
SG11201608430RA 2014-04-11 2015-04-08 Novel macrocyclic compounds SG11201608430RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014000392 2014-04-11
PCT/EP2015/057546 WO2015155197A1 (en) 2014-04-11 2015-04-08 Novel macrocyclic compounds

Publications (1)

Publication Number Publication Date
SG11201608430RA true SG11201608430RA (en) 2016-11-29

Family

ID=52824234

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608430RA SG11201608430RA (en) 2014-04-11 2015-04-08 Novel macrocyclic compounds

Country Status (28)

Country Link
US (1) US9963464B2 (en)
EP (1) EP3129387B1 (en)
JP (1) JP6605493B2 (en)
KR (1) KR102383938B1 (en)
CN (1) CN106459084B (en)
AP (1) AP2016009483A0 (en)
AR (1) AR099999A1 (en)
AU (1) AU2015243585B2 (en)
BR (1) BR112016023554B1 (en)
CA (1) CA2945237C (en)
CL (1) CL2016002577A1 (en)
CR (1) CR20160471A (en)
CU (1) CU24399B1 (en)
DO (1) DOP2016000278A (en)
EA (1) EA032541B1 (en)
ES (1) ES2743799T3 (en)
IL (1) IL247966B (en)
MX (1) MX2016013362A (en)
PE (1) PE20161379A1 (en)
PH (1) PH12016501968A1 (en)
SG (1) SG11201608430RA (en)
SV (1) SV2016005301A (en)
TN (1) TN2016000435A1 (en)
TW (1) TW201623312A (en)
UA (1) UA119349C2 (en)
UY (1) UY36072A (en)
WO (1) WO2015155197A1 (en)
ZA (1) ZA201607765B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108290903B (en) * 2015-09-29 2021-09-03 拜耳医药股份有限公司 Novel macrocyclic sulfondiimine compounds
CN108368129B (en) * 2015-10-08 2021-08-17 拜耳医药股份有限公司 Modified macrocyclic compounds
PT3445767T (en) * 2016-04-22 2020-05-13 Astrazeneca Ab Macrocyclic mcl1 inhibitors for treating cancer
RU2019111887A (en) * 2016-10-20 2020-11-20 Пфайзер Инк. ANTIPROLIFERATIVE DRUGS FOR PAH TREATMENT
US11242356B2 (en) 2017-03-28 2022-02-08 Bayer Aktiengesellschaft PTEFb inhibiting macrocyclic compounds
PL3601253T3 (en) 2017-03-28 2022-01-17 Bayer Aktiengesellschaft Novel ptefb inhibiting macrocyclic compounds
CN109251212A (en) * 2017-07-14 2019-01-22 上海长森药业有限公司 Inner ring sulfide amide-arylamides and its purposes for treating hepatitis B
CN111434665B (en) * 2019-01-11 2023-03-10 上海长森药业有限公司 Ensultamidenamide-arylamide compounds and their use for treating hepatitis B
CN112321604A (en) * 2019-08-05 2021-02-05 华东理工大学 Macrocyclic JAK2 inhibitor and application thereof
WO2023057812A1 (en) 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2556946T3 (en) 2000-12-21 2016-01-21 Novartis Ag Pyrimidinamines as angiogenesis modulators
DE10239042A1 (en) * 2002-08-21 2004-03-04 Schering Ag New fused macrocyclic pyrimidine derivatives, useful as e.g. cyclin-dependent kinase inhibitors for treating e.g. cancer, autoimmune, cardiovascular or neurodegenerative diseases or viral infections
DE10349423A1 (en) 2003-10-16 2005-06-16 Schering Ag Sulfoximine-substituted parimidines as CDK and / or VEGF inhibitors, their preparation and use as medicaments
KR20070091018A (en) 2004-12-17 2007-09-06 아스트라제네카 아베 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino)benzamides as cdk inhibitors
DE102006042143A1 (en) 2006-09-08 2008-03-27 Bayer Healthcare Aktiengesellschaft Novel substituted bipyridine derivatives and their use
WO2008060248A1 (en) 2006-11-15 2008-05-22 S*Bio Pte Ltd. Indole sustituted pyrimidines and use thereof in the treatment of cancer
KR20090101905A (en) 2006-12-22 2009-09-29 노파르티스 아게 Indol-4-yl-pyrimidinyl-2-yl-amine derivatives and use thereof as cyclin dependant kinase inhibitors
CA2672518A1 (en) 2006-12-22 2008-07-03 Novartis Ag Organic compounds and their uses
JP5566880B2 (en) 2007-04-24 2014-08-06 インゲニウム ファーマシューティカルズ ジーエムビーエイチ 4,6-disubstituted aminopyrimidine derivatives as inhibitors of protein kinases
JP5379787B2 (en) 2007-04-24 2013-12-25 インゲニウム ファーマシューティカルズ ジーエムビーエイチ Protein kinase inhibitors
ES2539518T3 (en) 2007-04-24 2015-07-01 Astrazeneca Ab Protein kinase inhibitors
WO2008132138A1 (en) 2007-04-25 2008-11-06 Ingenium Pharmaceuticals Gmbh Derivatives of 4,6-disubstituted aminopyrimidines
WO2009029998A1 (en) 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds
GB0805477D0 (en) 2008-03-26 2008-04-30 Univ Nottingham Pyrimidines triazines and their use as pharmaceutical agents
US8415381B2 (en) 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
AU2011231975B2 (en) 2010-03-22 2014-07-03 Bayer Intellectual Property Gmbh Pharmaceutically active disubstituted triazine derivatives
CN103562184B (en) 2011-03-02 2016-04-27 利德探索中心有限公司 The Disubstituted pyridine derivatives of pharmaceutical active
EP2527332A1 (en) 2011-05-24 2012-11-28 Bayer Intellectual Property GmbH 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
JP5976814B2 (en) 2011-09-16 2016-08-24 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH Disubstituted 5-fluoropyrimidine derivatives containing sulphoximine groups
WO2013037896A1 (en) * 2011-09-16 2013-03-21 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro-pyrimidines
CN105102434A (en) 2012-10-18 2015-11-25 拜耳药业股份公司 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing sulfone group
CN104918918B (en) 2012-11-15 2017-10-24 拜耳药业股份公司 The base amine of 45 fluoropyrimidine of (neighbour) fluorophenyl 2 of the imine group containing sulphur
LT2928878T (en) 2012-11-15 2016-11-25 Bayer Pharma Aktiengesellschaft 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group
WO2015001021A1 (en) 2013-07-04 2015-01-08 Bayer Pharma Aktiengesellschaft Sulfoximine substituted 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives and their use as cdk9 kinase inhibitors
US9856242B2 (en) 2014-03-13 2018-01-02 Bayer Pharma Aktiengesellscaft 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group

Also Published As

Publication number Publication date
EP3129387B1 (en) 2019-06-26
UA119349C2 (en) 2019-06-10
AU2015243585B2 (en) 2019-08-01
CR20160471A (en) 2016-12-21
CU20160152A7 (en) 2017-04-05
CA2945237C (en) 2022-09-06
KR20160136449A (en) 2016-11-29
UY36072A (en) 2015-11-30
CA2945237A1 (en) 2015-10-15
WO2015155197A1 (en) 2015-10-15
ZA201607765B (en) 2022-09-28
MX2016013362A (en) 2017-02-09
CL2016002577A1 (en) 2017-04-07
CN106459084A (en) 2017-02-22
JP2017510598A (en) 2017-04-13
EA032541B1 (en) 2019-06-28
AU2015243585A1 (en) 2016-10-13
AR099999A1 (en) 2016-08-31
CU24399B1 (en) 2019-04-04
BR112016023554A2 (en) 2017-08-15
PH12016501968A1 (en) 2016-12-19
KR102383938B1 (en) 2022-04-08
TW201623312A (en) 2016-07-01
ES2743799T3 (en) 2020-02-20
PE20161379A1 (en) 2017-01-15
BR112016023554B1 (en) 2023-03-14
US9963464B2 (en) 2018-05-08
TN2016000435A1 (en) 2018-04-04
US20170029439A1 (en) 2017-02-02
IL247966B (en) 2021-02-28
JP6605493B2 (en) 2019-11-13
AP2016009483A0 (en) 2016-10-31
DOP2016000278A (en) 2016-11-15
SV2016005301A (en) 2018-03-12
EA201692034A1 (en) 2017-04-28
CN106459084B (en) 2019-04-19
EP3129387A1 (en) 2017-02-15
IL247966A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
IL250345A0 (en) Novel compounds
IL250592A0 (en) Novel compounds
AP2017009836A0 (en) Aminopyridyloxypyrazole compounds
GB201417011D0 (en) Novel compounds
GB201417094D0 (en) Novel compounds
GB201417018D0 (en) Novel compounds
GB201402431D0 (en) Compounds
ZA201607765B (en) Novel macrocyclic compounds
AP2016009432A0 (en) Novel compounds
GB201405991D0 (en) Novel compounds
GB201411236D0 (en) Novel compounds
GB201411239D0 (en) Novel compounds
GB201404002D0 (en) Novel compounds
AP2017009778A0 (en) Azetidinyloxyphenylpyrrolidine compounds
IL248983A0 (en) Novel compounds
GB201419102D0 (en) Novel compounds
ZA201605726B (en) Novel compounds
GB201421834D0 (en) Novel compounds
GB201421784D0 (en) Novel compounds
GB201417021D0 (en) Novel compounds
GB201417041D0 (en) Novel compounds
GB201417043D0 (en) Novel compounds
GB201414614D0 (en) Novel compounds
GB201413451D0 (en) Novel compounds
GB201413260D0 (en) Novel compounds